# Study of the Human Anti-TNF Monoclonal Antibody Adalimumab for the Induction of Clinical Remission in Subjects With Crohn's Disease

> **NCT00105300** · PHASE3 · COMPLETED · sponsor: **Abbott** · enrollment: 300 (—)

## Conditions studied

- Crohn's Disease

## Interventions

- **DRUG:** Adalimumab

## Key facts

- **NCT ID:** NCT00105300
- **Lead sponsor:** Abbott
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2004-10
- **Primary completion:** —
- **Final completion:** —
- **Target enrollment:** 300 (—)
- **Last updated:** 2006-08-15


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00105300

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00105300, "Study of the Human Anti-TNF Monoclonal Antibody Adalimumab for the Induction of Clinical Remission in Subjects With Crohn's Disease". Retrieved via AI Analytics 2026-06-01 from https://api.ai-analytics.org/clinical/NCT00105300. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*